private:trevitherapeutics
|
2073467
|
Dec 3rd, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
834
|
25.00
|
Open
|
Biotechnology
|
Dec 3rd, 2020 03:05PM
|
Dec 3rd, 2020 03:05PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Dec 2nd, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
834
|
25.00
|
Open
|
Biotechnology
|
Dec 2nd, 2020 04:53PM
|
Dec 2nd, 2020 04:53PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Dec 1st, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
834
|
25.00
|
Open
|
Biotechnology
|
Dec 1st, 2020 03:25PM
|
Dec 1st, 2020 03:25PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Nov 30th, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
832
|
25.00
|
Open
|
Biotechnology
|
Nov 29th, 2020 09:24PM
|
Nov 30th, 2020 04:12PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Nov 28th, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
832
|
25.00
|
Open
|
Biotechnology
|
Nov 28th, 2020 04:58PM
|
Nov 28th, 2020 04:58PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Nov 27th, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
830
|
25.00
|
Open
|
Biotechnology
|
Nov 27th, 2020 01:24PM
|
Nov 27th, 2020 01:24PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Nov 26th, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
830
|
25.00
|
Open
|
Biotechnology
|
Nov 25th, 2020 08:25PM
|
Nov 25th, 2020 08:25PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Nov 24th, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
830
|
25.00
|
Open
|
Biotechnology
|
Nov 24th, 2020 03:58PM
|
Nov 24th, 2020 03:58PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Nov 23rd, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
828
|
25.00
|
Open
|
Biotechnology
|
Nov 23rd, 2020 05:47PM
|
Nov 23rd, 2020 05:47PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
private:trevitherapeutics
|
2073467
|
Nov 22nd, 2020 12:00AM
|
Trevi Therapeutics, Inc.
|
828
|
24.00
|
Open
|
Biotechnology
|
Nov 22nd, 2020 04:43PM
|
Nov 22nd, 2020 04:43PM
|
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
|
Open
|
|
Open
|
195 Church Street, 14th Floor
|
New Haven
|
CT
|
US
|
06510
|
|
Trevi Therapeutics
|
Health Care
|
Health Care Equipment & Services
|